Iveric Bio   Report issue

For profit Phase 1 Phase 3
Founded: Princeton NJ United States (2007)

Organization Overview

First Clinical Trial
2007
NCT00569140
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

IVERIC bio, Inc. | Ophthotech Corporation

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrophy (Phase 3)

Geographic Atrophy (Phase 3)

Macular Degeneration (Phase 3)

Vascular Diseases (Phase 2)

Wet Macular Degeneration (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 19
  • # of Trial APIs: 7